59 results about "Virus Binding" patented technology

The present invention concerns methods and compositions for subunit-based vaccines for inducing immunity against poxvirus infections, such as smallpox. Preferred embodiments concern immunoconjugates comprising one or more subunit antigenic peptides attached to an antibody or fragment thereof that targets antigen-producing cells (APCs). More preferably, the antibody binds to HLA-DR and the antigenic peptide is from an immunomodulating factor, such as the viral IL-18 binding protein (vIL18BP). However, mixtures of antigenic peptides from different viral proteins may also be used. The vaccine is capable of inducing immunity against poxvirus without risk of disseminated infection in immunocompromised hosts or transmission to susceptible contacts.

The present invention relates to the field of detection of viruses, and in particular to detection of viruses using a liquid crystal assay format. In the present invention, virus binding in a detection region is identified by changes in liquid crystal orientation caused by virus binding independent orientation caused by any topography associated with the detection region.

The present invention uses the replaseable biosensor chip technology as core, and uses the related MEMS system formed from microreactor and microflow cell to make determination of environment pollution. After the harmfule molecule (for example influenza virus or SARS virus) is combined on the functional chip, said polluted molecule can store the information, and can release it in specific environment, and its released information is directly propertional to the polluted extent, so that it can implement the determination of environmental pollution.

The present invention relates to the field of detection of viruses, and in particular to detection of viruses using a liquid crystal assay format. In the present invention, virus binding in a detection region is identified by changes in liquid crystal orientation caused by virus binding independent orientation caused by any topography associated with the detection region.

The instant disclosure provides norovirus-binding aptamers, compositions comprising such aptamers, and methods of using and producing such aptamers. The aptamers are useful, for example, for detecting the presence of norovirus in test samples, for capturing and / or concentrating norovirus from test samples, for evaluating the efficacy of therapeutic agents in patients diagnosed with a norovirus infection, and for evaluating the efficacy of norovirus vaccines.

The invention discloses a virus detector, which comprises an interdigital array microelectrode (1), a micro fluidic detection pool (2) and an impedance detection module (3); when a sample containing virus is injected into the micro fluidic detection pool (2), an antibody or other biological identification materials fixed on the surface of the interdigital array microelectrode (1) embedded in the micro fluidic detection pool (2) can be combined with virus, impedance change is generated, impedance measure is carried out through an impedance detection module (3), data processing is carried out by using a standard curve, so that bird flu virus content can be rapidly and quantitatively determined. The virus detector has the advantages of fast detection speed, convenient operation, quantitative analysis and on-site detection.

Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif.

Methods for obtaining modified proteins or virus with an intact native binding site and decreased antigenicity and modified proteins or virus obtainable by said methods are provided. The methods of protein or virus modification comprise masking with non-immunogenic molecules the protein or the virus surface, except for the protein or the virus binding site. Examples of modified proteins or virus that can be modified in accordance to the methods include polyclonal or monoclonal antibodies, modified replication-defective virus, hormones, and enterotoxins.

The invention relates to the field of separation and purification of virus, in particular to a separation and purification method of adeno-associated virus. The method comprises the following steps: a) providing a chromatography medium which comprises a matrix support and an antibody fixed on the matrix support, and the sequences of a heavy chain variable region and a light chain variable region of the antibody are shown as SEQ ID NO: 1 and SEQ ID NO: 2 in sequence; b) co-incubating a liquid phase composition comprising an adeno-associated virus with the chromatography medium such that the adeno-associated virus binds to the antibody; and c) eluting the adeno-associated virus from the antibody, wherein the adeno-associated virus is selected from any one or more of AAV1-13. According to themethod, any one of AAV1-13 can be universally separated and purified, and the AAV does not need to be transformed, so that the AAV is more convenient to purify; the purification efficiency is high, the specificity is good, and the detectable nonspecific binding with other proteins in cells is hardly generated.

A pharmaceutical composition for treating viral infections by an influenza type A virus, includes a compound capable of acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of influenza type A viruses, and capable of binding to the viral-RNA-binding domain on the nucleoprotein. A pharmaceutical composition for treating viral infections by an orthomyxovirus, includes a compound capable of acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of orthomyxoviruses, and capable of binding to the viral-RNA-binding domain on the nucleoprotein of the viruses. A compound acting as an inhibitor of the binding of the viral RNA to the nucleoprotein of influenza type A viruses, and binding to the viral-RNA-binding domain on the nucleoprotein of influenza type A viruses and a method for identifying such a compound having these properties are also described.

The invention discloses a cyclic peptide combined with an RBD site of novel coronavirus as well as a preparation method and application of the cyclic peptide, and particularly relates to a cyclic polypeptide molecule obtained through in-vitro amino acid side chain cyclization, amino acid point mutation and dimerization modification on the basis of an angiotensin converting enzyme 2 (ACE2) core sequence combined with the RBD of novel coronavirus. The cyclic polypeptide disclosed by the invention can be used for preparing a polypeptide drug with an SARS-CoV-2 virus inhibition effect, or used for preparing a detection reagent for detecting SARS-CoV-2, and a bioactive lead molecule with commercial value is provided for treatment and detection of SARS-CoV-2.

The subject invention provides materials and methods for improving animal resistance to infection by intestinal viruses. This is accomplished by interfering with intestinal virus uptake employing methods that (1) reduce virus binding to receptors in the intestinal lining; (2) introduce decoy receptors expressed in the mammary gland leading to decoy secretion in milk; (3) produce decoy receptors by a variety of protein synthesis methods to provide decoy receptors to non-genetically modified animals, including humans; and / or (4) administer a vector to a non-genetically modified animal which vector has been genetically modified to produce a decoy receptor.

The invention discloses novel coronavirus detection equipment. The equipment comprises a light source, a polarization control device, a detection optical fiber and a spectrograph; the output end of the light source is connected with the polarization control device, and the output end of the polarization control device is connected with the input end of the detection optical fiber; the output end of the detection optical fiber is connected with the input end of the spectrograph; and a metal nano-film layer is arranged on the surface of a detection section of the detection optical fiber, and a novel coronavirus antibody is arranged on the surface of the metal nano-film layer. The novel coronavirus antibody is arranged on the metal nano-film layer on the surface of the detection optical fiber, and the novel coronavirus can be conveniently and rapidly detected on the basis of the principle that light waves generating plasma resonance on the surface of the metal nano-film layer deviate before and after the novel coronavirus antibody and the new coronavirus are combined, and rapid troubleshooting of a novel coronavirus carrier is facilitated. The invention further provides a preparationmethod of the detection optical fiber of the novel coronavirus detection equipment. The above beneficial effects are also achieved.

The invention discloses a gel dressing for preventing and treating human papillomavirus infection. The gel dressing is prepared by taking a CP protein, carbomer, carboxylated chitosan, glycerol and Arabic gum as main raw materials, wherein the mass percentages of the raw materials are as follows: 0.01-0.1% of the CP protein, 0.1-1% of the carbomer, 0.1-1% of the carboxylated chitosan, 5-15% of theglycerol, 0.5-3% of the Arabic gum and the balance of water. According to the invention, the CP protein is used as a main effective component, and the whole CP protein is negatively charged, can be combined with HPV viruses to inactivate the HPV viruses, and has repair capability on damaged tissues. The invention also discloses an application of the gel dressing in preparing medicaments for preventing and treating human papillomavirus infection.

This invention teaches a novel treatment of patients infected with influenza virus in early stages of the disease, with liposomes called α-gal / SA liposomes, in order to decrease the infection period and decrease further complications by this disease. The treatment is based on inhalation of biodegradable liposomes that present two types of carbohydrate epitopes: α-Gal epitopes with the structure Galα1-3Galβ1-4(3)GlcNAc-R) and sialic acid (SA) epitopes. The treatment is based on the ability of influenza virus to bind to SA epitopes and on the binding of the natural anti-Gal antibody (the most abundant natural antibody in humans) to α-gal epitopes. Following inhalation of aerosolized α-gal / SA liposomes they land in the mucus lining the respiratory tract. The α-gal / SA liposomes bind influenza virus via SA epitopes interaction with hemagglutinin of the virus, thus they slow or prevent the progress of the influenza virus infection process. Binding of the natural anti-Gal antibody to α-gal epitopes on α-gal / SA liposomes causes complement mediated chemotactic recruitment of macrophages and dendritic cells which internalize via Fc / Fc receptor interaction the α-gal / SA liposomes and the influenza virus bound to them and destroy this virus. The recruited macrophages and dendritic cells further process the immunogenic peptides of the internalized virus, transported them to the regional lymph nodes and present these peptides for eliciting an effective protective immune response that ends the influenza virus infection in a period shorter than in untreated patients and prevents further complications in the respiratory system and in other parts of the body.

The invention relates to a traditional Chinese medicine composition, belonging to the field of medicine, in particular to a tuberculosis pill and a preparation method thereof. 150g tortoise shell, 100g oyster, 100g turtle shell, 100g Rehmannia glutinosa, 100g Rehmannia glutinosa, 50g, 150g Asparagus, 100g donkey-hide gelatin, 100g North ginseng, 50g keel, 50g amethyst, 50g Ophiopogon japonicus, 25g cooked rhubarb, white and 100g , Fritillaria 100g, beeswax 100g. Said tortoise shell and turtle shell are made of vinegar, Baibu is made of honey moxibustion, and amethyst is made of calcined. The preparation method is as follows: the medicinal materials that are difficult to be extracted by the decoction method are crushed into medicinal powder, and the remaining medicinal materials are extracted into medicinal liquid and condensed into a thick paste, which is prepared by mixing medicinal powder and extract in a ratio of 3.5:1. The beneficial effects are: nourishing yin and nourishing blood, invigorating lung and clearing heat, promoting calcification of lung cavity, good curative effect, effectively killing bound virus, being made of pure traditional Chinese medicine, high extraction purity and less loss of medicine.

The invention provides a human angiotensin converting enzyme 2-based affinity polypeptide for the severe acute respiratory syndrome coronavirus 2, and relates to the technical field of biological materials. Key human angiotensin converting enzyme 2 amino acid residues of binding sites of human angiotensin converting enzyme 2 and the severe acute respiratory syndrome coronavirus 2 are extracted toreconstruct a peptide library, and the human angiotensin converting enzyme 2-based affinity polypeptide for the severe acute respiratory syndrome coronavirus 2 is obtained by screening; and then, a biological detection reagent is prepared from the affinity polypeptide, and thus, a new method is provided for detection of the severe acute respiratory syndrome coronavirus 2.

The invention relates to a polypeptide and a gold nano-antibody capable of targeting an HIV (human immunodeficiency virus) envelope protein gp120. The artificial antibody consists of gold nanoparticles and a section of designed polypeptide sequence. The prepared gold nano-antibody can enhance the binding strength of a drug to a target, namely, when the concentration of the virus gp120 in the bodyis very low, the binding strength can be maintained at a high level. At the same time, the gold nano-antibody has the characteristics of small particle size, excellent dispersibility, good stability and the like, can reach the parts which cannot be reached by common drugs, and can bind to viruses more strongly. Therefore, the artificial antibody has broad application prospects in the field of biomedicine.

The present invention relates to a method for treating cancer in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a Coxsackie B3 group virus or a modified form thereof, wherein the cells of the cancer express a heparan sulfate (HS) receptor on their surface and the virus binds to said HS receptor, enters and accumulates in the cancer cells, whereby at least some cancer cells undergo viral lysis.

The present invention relates to a KSHV virus vIRF4 DNA binding domain and a polyclonal antibody thereof, and a preparation method of the polyclonal antibody. According to the present invention, the KSHV virus vIRF4 DNA binding domain is subjected to recombinant expression by using a genetic engineering technology, and the murine polyclonal antibody is prepared by immunizing animals, wherein the antibody has excellent binding specificity.

The invention relates to the technical field of veterinary drugs, in particular to a compound plant extract preparation for preventing and treating porcine viral diseases and application thereof. Effective components such as compound plant polysaccharide and saponin are used, and the content of the components is controlled, so that the autoimmunity of animals is regulated, and the virus infectionthreshold value is increased; and plant polysaccharide components are combined with virus binding targets to block virus adhesion. By standardizing key index components and contents, the quality of the compound plant extract product is controllable, and the virus prevention and treatment effect of the preparation is guaranteed. Warm-tonifying plants free of obvious harmful substances are selectedas raw materials, so that long-term group administration can be realized, the extraction method is simple, only simple filtration is required, further purification is not required, and the cost is reduced. The compound plant extract preparation has the auxiliary effects of promoting appetite of pigs and other livestock, resisting oxidation and stress, inducing diuresis, expelling toxin, promotingyield increase and the like, and the application range is widened.

The invention discloses a recombinant protein for detecting a hog cholera virus. The recombinant protein is encoded by a fusion gene which is formed by splicing a surface antigen single-chain antibody gene of anti-human red blood cell H and an envelop glycoprotein single-chain antibody gene of anti-hog cholera virus E2. The recombinant protein has a double-function characteristic, can be conjugated with the human red blood cell without agglutination and further conjugated with the hog cholera virus, and under the virus binding action, generates agglutination megascopically. The recombinant protein can be used for detecting the hog cholera virus, is simple in operation, high in flexibility and strong in specificity, and can meet the requirement of quickness, simpleness and convenience for use in the grass-root level field.

The present invention relates to the use of a phage blocking assay to determine unknown binding molecule present on or in the surface of a cell, a non-infectious moiety, a bacteria, a virus, or another pathogen. In particular embodiments, the invention relates to the identification of unknown receptors on a cell or virus involved in infection. Further, it relates to the use of said binding molecules, for example virus binding molecules or cellular receptors and binding members with binding specificity to said binding molecules, for example antibodies, in methods of therapy.

The invention discloses a GK-7 oligopeptide for resisting novel coronavirus infection. The amino acid sequence of the GK-7 oligopeptide is GKGDFRI. The invention further discloses a preparation methodand application of the GK-7 oligopeptide. The GK-7 oligopeptide is derived from human body protein, contains key residues of a virus-binding cell receptor, and is simple to prepare and good in clinical application prospect.

The invention is directed to the treatment of COVID-19 patients by administering to patients either infected by SARS-CoV-2 or presymptomatic for COVID-19 but at risk of severe morbidity and mortality due to potential COVID-19 infection. Such patients are given modified pectin, preferably modified citrus pectin, in an amount that may range from 2.5 or 5 on up to 10-25 grams per day, divided into two or three doses per day. The administration may be oral, by inhalation, intrabuccal or IV. The process may be combined with the administration of supportive agents like antivirals, anti-inflammatories, immune based inhibitors, vitamins, monoclonal and polyclonal anti-viral or viral binding antibodies.

The present invention provides humanized antibodies and antigen binding fragments thereof that bind to human poliovirus (PVR). The antibodies can be used to treat tumors or cancers.

The present invention relates to a method for treating cancer in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a Coxsackie B3 group virus or a modified form thereof, wherein the cells of the cancer express a heparan sulfate (HS) receptor on their surface and the virus binds to said HS receptor, enters and accumulates in the cancer cells, whereby at least some cancer cells undergo viral lysis.

The invention relates to an antibacterial gray fabric preparation method which includes the steps: dissolving acrylic elastic emulsion, softening agents, antibacterial solution, talcum powder and polyoxyethylene in distilled water by weight, and uniformly stirring mixture for a period of time by a stirrer; pouring mixed materials into a spinning machine, and heating the mixed materials to reach acertain temperature until the materials are molten; extruding the molten raw materials to from mixed fibers, and blending the mixed fibers, polyester, animal fibers, cotton fibers and flame retardantpolyester fibers to form a gray fabric; placing the gray fabric into the antibacterial solution to soak the gray fabric for a period of time, taking out the gray fabric, and drying the gray fabric toprepare the gray fabric. The gray fabric can effectively prevent bacteria, fungi and mildew on a fabric, and cleanness of the fabric is kept, so that antibacterial performance is improved. As silver ions and iodide ions in the antibacterial solution can penetrate the fabric, the fabric contains the silver ions and the iodide ions, the prepared antibacterial gray fabric has an antibacterial function, various bacteria and viruses bound on the gray fabric can be killed in the use process, and health of a user is guaranteed.

The invention relates to a preparation method of a virus stock solution. The host cells are cleaned with a serum-free medium; dextran, phosphate buffer and virus are prepared into a mixed solution; the mixed solution is added to the treated host cells Carry out adsorption infection; culture the treated host cells with a medium containing fetal bovine serum; freeze and thaw the treated host cells to release the virus, and then centrifuge to obtain the virus stock solution. The present invention replaces polybrene by adopting dextran, because dextran itself is a kind of cationic polymer, it is combined with the negatively charged virus and is close to the cell membrane to be taken up, and has no toxic effect on the cell itself, fundamentally In fact, it can improve the growth rate and proliferation efficiency of host cells, and play a significant role in promoting the amplification of viruses, so that the virus titer of the prepared virus stock solution is high.